Contraception method using competitive progesterone antagonists and novel compounds useful therein
AssigneeSchering Corporation
InventorsKrzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
Life of this patent
Estimating the term…
Abstract
Competitive progesterone antagonists, including two novel steroids, viz., 11β,19-[4-(cyanophenyl)-o-phenylene]-17β-hydroxy-17α-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11β,19-[4-(3-pyridinyl)-o-phenylene]-17β-hydroxy-17α-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
Claims11
A method of implantation inhibition in a female, which comprises administering thereto during the follicular phase of her menstrual cycle and optionally also in the luteal phase thereof an amount of a competitive progesterone antagonist, which is less than an ovulation-inhibiting dose and less than an abortion-inductive dose and which is effective to inhibit the formation of endometrial glands and epithelium growth.
Dependencies are inferred from the claim text.